Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06, Bloomberg Earnings reports. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.81 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%.

Chimerix (NASDAQ:CMRX) traded down $0.07 during trading on Thursday, reaching $4.76. The company had a trading volume of 169,945 shares, compared to its average volume of 298,431. Chimerix has a twelve month low of $4.28 and a twelve month high of $6.64.

Several analysts have issued reports on CMRX shares. ValuEngine lowered Chimerix from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Wednesday, August 9th.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Earnings History for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with's FREE daily email newsletter.